2021/02/18

Yakuji Nippo

Joint research between industry-academia-government to create new drugs-Building an integrated database of disease-specific information


株式会社薬事日報社から許諾を受けて、株式会社シーエムプラスが英語に翻訳しております。
オリジナルの正式言語は日本語であり、内容および解釈については日本語が優先されます。
With permission from Yakuji Nippo, Limited, CM Plus Corporation translated into English.
The original article is authored in Japanese, and the Japanese shall prevail in meaning in terms of content and interpretation.

【JPMA / NCBN】
Joint research between industry-academia-government to create new drugs-Building an integrated database of disease-specific information

January 27th, 2021

Seven member companies of  the Japan Pharmaceutical Manufacturers Association (JPMA) and the National Center Biobank Network (NCBN) announced on December 25 that they will start joint research on building and utilizing an integrated database of disease-specific information that is expected to be used in developing  new drugs and personalized medicine. The joint research is carried out until March 2025. After obtaining omics data such as genetic information and protein from patient-derived samples attached to clinical information held by NCBN, industry-academia-government jointly builds an integrated database of disease-specific information by combining analysis results with clinical information such as laboratory data and image data.

(Continue to the next)


For this translated article in English, CM Plus Corporation shall have the copyright.
Unauthorized reproduction of posted articles, photos, diagrams, etc. is prohibited.
Copyright © 2021 LSMIP office / CM Plus Singapore Pte. Ltd.

A Series of Articles

About the Author

Related Articles

No information is found.